Influence of Genotype on Structural Atrial Abnormalities and Atrial Fibrillation or Flutter in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy

Structural Atrial Involvement in ARVD/C Introduction Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) is associated with desmosomal mutations. Although desmosomal disruption affects both ventricles and atria, little is known about atrial involvement in ARVD/C. Objective To describe...

Full description

Saved in:
Bibliographic Details
Published inJournal of cardiovascular electrophysiology Vol. 27; no. 12; pp. 1420 - 1428
Main Authors BOURFISS, MIMOUNT, TE RIELE, ANNELINE S.J.M., MAST, THOMAS P., CRAMER, MAARTEN J., VAN DER HEIJDEN, JEROEN F., VAN VEEN, TOON A.B., LOH, PETER, DOOIJES, DENNIS, HAUER, RICHARD N.W., VELTHUIS, BIRGITTA K.
Format Journal Article
LanguageEnglish
Published United States Blackwell Publishing Ltd 01.12.2016
Wiley Subscription Services, Inc
Subjects
Online AccessGet full text
ISSN1045-3873
1540-8167
1540-8167
DOI10.1111/jce.13094

Cover

More Information
Summary:Structural Atrial Involvement in ARVD/C Introduction Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) is associated with desmosomal mutations. Although desmosomal disruption affects both ventricles and atria, little is known about atrial involvement in ARVD/C. Objective To describe the extent and clinical significance of structural atrial involvement and atrial arrhythmias (AA) in ARVD/C stratified by genotype. Methods We included 71 patients who met ARVD/C Task Force Criteria and underwent cardiac magnetic resonance (CMR) imaging and molecular genetic analysis. Indexed atrial end‐diastolic volume and area‐length‐ejection‐fraction (ALEF) were evaluated on CMR and compared to controls with idiopathic right ventricular outflow tract tachycardia (n = 40). The primary outcome was occurrence of AA (atrial fibrillation or atrial flutter) during follow‐up, recorded by 12‐lead ECG, Holter monitoring or implantable cardioverter defibrillator (ICD) interrogation. Results Patients harbored a desmosomal plakophilin‐2 (PKP2) (n = 37) or nondesmosomal phospholamban (PLN) (n = 14) mutation. In 20 subjects, no pathogenic mutation was identified. Compared to controls, right atrial (RA) volumes were reduced in PKP2 (P = 0.002) and comparable in PLN (P = 0.441) mutation carriers. In patients with no mutation identified, RA (P = 0.011) and left atrial (P = 0.034) volumes were increased. Bi‐atrial ALEF showed no significant difference between the groups. AA were experienced by 27% of patients and occurred equally among PKP2 (30%) and no mutation identified patients (30%), but less among PLN mutation carriers (14%). Conclusion Genotype influences atrial volume and occurrence of AA in ARVD/C. While the incidence of AA is similar in PKP2 mutation carriers and patients with no mutation identified, PKP2 mutation carriers have significantly smaller atria. This suggests a different arrhythmogenic mechanism.
Bibliography:ark:/67375/WNG-Z917M243-5
Table S1. Pathogenic Mutations Identified in ARVD/C Patients. No. = number; PKP2 = plakophilin-2; PLN = phospholamban.Table S2. ARVD/C Patients Stratified in Probands and Family Members. Mean values ± standard deviation; number (%); *Fisher exact test; AA = atrial arrhythmias; ICD = implantable cardioverter defibrillator.
Dutch Heart Association - No. 2015T058
istex:59562C9C60DDA53D015366EE1100865FC06B964E
Heart Rhythm Society: Clinical Research Award in Honor of Mark Josephson and Hein Wellens
ArticleID:JCE13094
Disclosures: None.
This work was supported by the Dutch Heart Association (2015T058 to Dr. Te Riele).
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:1045-3873
1540-8167
1540-8167
DOI:10.1111/jce.13094